Official Title
A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)
Brief Summary

A Trial of GC4419 in Patients with Critical Illness due to COVID-19

Terminated
COVID19
SARS-CoV-2 Infection

Drug: GC4419

180 Minute IV Infusion
Other Name: Avasopasem

Drug: Placebo

180 Minute IV Infusion

Eligibility Criteria

Inclusion Criteria:

1. Male or female subjects at least 18 years of age.

2. Ability to understand and the willingness to sign a written informed consent.

3. Laboratory-confirmed SARS-CoV-2 infection as determined by a positive PCR test
documented prior to randomization

4. Requirement for intensive inpatient hospital care

5. Acute hypoxemic respiratory failure typifying ARDS

6. Adequate liver function

7. Use of effective contraception

Exclusion Criteria:

1. Expected survival for less than 48 hours after randomization

2. Child-Pugh stage C hepatic impairment and/or portal hypertension secondary to
cirrhosis

3. Stage IV chronic kidney disease or end-stage kidney disease on maintenance
hemodialysis

4. Requirement for extra-corporeal membrane oxygenation (ECMO)

5. Acute Myocardial Infarction (AMI)

6. Active bleeding requiring transfusion

7. Concurrent participation in another clinical trial of experimental treatment for
SARSCoV-2

8. Female patients who are pregnant or breastfeeding

9. Requirement for concurrent treatment with nitrates

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
United States
Locations

University of Iowa
Iowa City, Iowa, United States

Saint Louis University
Saint Louis, Missouri, United States

Mercy Research
Saint Louis, Missouri, United States

Jon Holmlund, MD, Study Chair
Study Chair

Galera Therapeutics, Inc.
NCT Number
Keywords
COVID19
SARS-CoV-2 infection
MeSH Terms
Infections
COVID-19
Critical Illness
Avasopasem manganese